Home LiteratureArticle Details
PMID: 19327032 Published · ppublish English Journal Article Review

APOE-4 genotype and neurophysiological vulnerability to Alzheimer's and cognitive aging.

Annual review of clinical psychology ·Vol. 5 ·2009-00-00 ·Pages 343-62

Bookheimer S, Burggren A

Abstract

Many years before receiving a clinical diagnosis of Alzheimer's disease (AD), patients experience evidence of cognitive decline. Recent studies using a variety of brain imaging technologies have detected subtle changes in brain structure and function in normal adults with a genetic risk for AD; these brain changes have similar pathological features as AD, and some appear to be predictive of future cognitive decline. This review examines the most recent data on brain changes in genetic risk for AD and discusses the benefits and potential risks of detecting individuals at risk.

MeSH Terms
Aged Alleles Alzheimer Disease/epidemiology,genetics,physiopathology Apolipoprotein E4/genetics Brain/metabolism,pathology,physiopathology Cognition Disorders/diagnosis,epidemiology,physiopathology Genotype Humans Magnetic Resonance Imaging Middle Aged Neuropsychological Tests Positron-Emission Tomography Risk Factors
Chemicals
Apolipoprotein E4
Authors & Affiliations
2 authors, click to expand affiliations / ORCID
Bookheimer Susan
Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine, University of California-Los Angeles, CA 90095, USA. sbook@ucla.edu
Burggren Alison
References (114)
114 references, click to expand
  1. Cognitive domain decline in healthy apolipoprotein E epsilon4 homozygotes before the diagnosis of mild cognitive impairment.
    Arch Neurol. 2007 Sep;64(9):1306-11 PMID: 17846270
  2. Brain reserve and the prevention of dementia.
    Curr Opin Psychiatry. 2008 May;21(3):296-302 PMID: 18382231
  3. Apolipoprotein E polymorphism influences the cerebral metabolic pattern in Alzheimer's disease.
    Neurosci Lett. 1998 Sep 18;254(1):49-52 PMID: 9780089
  4. Mapping hippocampal and ventricular change in Alzheimer disease.
    Neuroimage. 2004 Aug;22(4):1754-66 PMID: 15275931
  5. Brain metabolic decreases related to the dose of the ApoE e4 allele in Alzheimer's disease.
    J Neurol Neurosurg Psychiatry. 2004 Mar;75(3):370-6 PMID: 14966149
  6. Curcuminoids enhance amyloid-beta uptake by macrophages of Alzheimer's disease patients.
    J Alzheimers Dis. 2006 Sep;10(1):1-7 PMID: 16988474
  7. Donepezil for the treatment of behavioral disturbances in Alzheimer's disease: a 6-month open trial.
    Arch Gerontol Geriatr. 2001 Nov-Dec;33(3):237-41 PMID: 15374020
  8. Health behavior changes after genetic risk assessment for Alzheimer disease: The REVEAL Study.
    Alzheimer Dis Assoc Disord. 2008 Jan-Mar;22(1):94-7 PMID: 18317253
  9. Verbal paired-associate learning by APOE genotype in non-demented older adults: fMRI evidence of a right hemispheric compensatory response.
    Neurobiol Aging. 2007 Feb;28(2):238-47 PMID: 16434125
  10. Therapeutic recreation interventions for need-driven dementia-compromised behaviors in community-dwelling elders.
    Am J Alzheimers Dis Other Demen. 2002 Nov-Dec;17(6):367-81 PMID: 12501484
  11. Midlife Neuroticism and the age of onset of Alzheimer's disease.
    Psychol Med. 2009 Apr;39(4):665-73 PMID: 18694539
  12. Evidence of linkage and association on chromosome 20 for late-onset Alzheimer disease.
    Neurogenetics. 2004 Jun;5(2):121-8 PMID: 15034766
  13. Hippocampal activation in adults with mild cognitive impairment predicts subsequent cognitive decline.
    J Neurol Neurosurg Psychiatry. 2008 Jun;79(6):630-5 PMID: 17846109
  14. Exercise plus behavioral management in patients with Alzheimer disease: a randomized controlled trial.
    JAMA. 2003 Oct 15;290(15):2015-22 PMID: 14559955
  15. Physical activity and cognitive decline, the role of the apolipoprotein e4 allele.
    Med Sci Sports Exerc. 2001 May;33(5):772-7 PMID: 11323547
  16. Cortical morphology in children and adolescents with different apolipoprotein E gene polymorphisms: an observational study.
    Lancet Neurol. 2007 Jun;6(6):494-500 PMID: 17509484
  17. Galantamine treatment of problematic behavior in Alzheimer disease: post-hoc analysis of pooled data from three large trials.
    Am J Geriatr Psychiatry. 2005 Jun;13(6):527-34 PMID: 15956273
  18. FDG-PET improves accuracy in distinguishing frontotemporal dementia and Alzheimer's disease.
    Brain. 2007 Oct;130(Pt 10):2616-35 PMID: 17704526
  19. Inhibition of COX-2 reduces the age-dependent increase of hippocampal inflammatory markers, corticosterone secretion, and behavioral impairments in the rat.
    J Neurosci Res. 2002 May 1;68(3):337-43 PMID: 12111864
  20. Women at risk for AD show increased parietal activation during a fluency task.
    Neurology. 2002 Apr 23;58(8):1197-202 PMID: 11971086
  21. Genetic association of ubiquilin with Alzheimer's disease and related quantitative measures.
    Mol Psychiatry. 2006 Mar;11(3):273-9 PMID: 16302009
  22. Lack of an association between Alzheimer's disease and the cystatin C (CST3) gene G73A polymorphism in Mainland Chinese.
    Dement Geriatr Cogn Disord. 2008;25(5):461-4 PMID: 18408364
  23. Impact of rivastigmine use on the risk of nursing home placement in a US sample.
    CNS Drugs. 2004;18(15):1143-8 PMID: 15581384
  24. Functional MRI studies of associative encoding in normal aging, mild cognitive impairment, and Alzheimer's disease.
    Ann N Y Acad Sci. 2007 Feb;1097:146-55 PMID: 17413017
  25. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families.
    Science. 1993 Aug 13;261(5123):921-3 PMID: 8346443
  26. Preclinical evidence of Alzheimer's disease in persons homozygous for the epsilon 4 allele for apolipoprotein E.
    N Engl J Med. 1996 Mar 21;334(12):752-8 PMID: 8592548
  27. Alzheimer's disease associated with mutations in presenilin 2 is rare and variably penetrant.
    Hum Mol Genet. 1996 Jul;5(7):985-8 PMID: 8817335
  28. Effects of simvastatin on cerebrospinal fluid biomarkers and cognition in middle-aged adults at risk for Alzheimer's disease.
    J Alzheimers Dis. 2008 Mar;13(2):187-97 PMID: 18376061
  29. Prevalence of pathogenic mutations in an Italian clinical series of patients with familial dementia.
    Curr Alzheimer Res. 2004 Aug;1(3):215-8 PMID: 15975068
  30. Will anti-amyloid therapies work for Alzheimer's disease?
    Lancet. 2008 Jul 19;372(9634):180-2 PMID: 18640437
  31. Capitalizing on cortical plasticity: influence of physical activity on cognition and brain function.
    Trends Cogn Sci. 2007 Aug;11(8):342-8 PMID: 17629545
  32. Identification of Alzheimer disease risk by functional magnetic resonance imaging.
    Arch Neurol. 2005 Dec;62(12):1881-8 PMID: 16344346
  33. Recruitment of anterior dorsolateral prefrontal cortex in human reasoning: a parametric study of relational complexity.
    Cereb Cortex. 2002 May;12(5):477-85 PMID: 11950765
  34. Diagnosis and treatment of Alzheimer disease and related disorders. Consensus statement of the American Association for Geriatric Psychiatry, the Alzheimer's Association, and the American Geriatrics Society.
    JAMA. 1997 Oct 22-29;278(16):1363-71 PMID: 9343469
  35. Cerebral glucose metabolism in patients with AD and different APOE genotypes.
    Neurology. 2005 Jan 11;64(1):102-7 PMID: 15642911
  36. The influence of APOE status on episodic and semantic memory: data from a population-based study.
    Neuropsychology. 2006 Nov;20(6):645-57 PMID: 17100509
  37. Amyloid-associated depression: a prodromal depression of Alzheimer disease?
    Arch Gen Psychiatry. 2008 May;65(5):542-50 PMID: 18458206
  38. Amyloid deposition begins in the striatum of presenilin-1 mutation carriers from two unrelated pedigrees.
    J Neurosci. 2007 Jun 6;27(23):6174-84 PMID: 17553989
  39. Role of 5HT 2A and 5HT 2C polymorphisms in behavioural and psychological symptoms of Alzheimer's disease.
    Neurobiol Aging. 2008 Mar;29(3):341-7 PMID: 17098333
  40. A systematic review of perceived risks, psychological and behavioral impacts of genetic testing.
    Genet Med. 2008 Jan;10(1):19-32 PMID: 18197053
  41. Clinical practice with anti-dementia drugs: a consensus statement from British Association for Psychopharmacology.
    J Psychopharmacol. 2006 Nov;20(6):732-55 PMID: 17060346
  42. Genetic risk assessment for adult children of people with Alzheimer's disease: the Risk Evaluation and Education for Alzheimer's Disease (REVEAL) study.
    J Geriatr Psychiatry Neurol. 2005 Dec;18(4):250-5 PMID: 16306249
  43. Emotional reactions to predictive testing in Alzheimer's disease and other inherited dementias.
    Am J Alzheimers Dis Other Demen. 2005 Jul-Aug;20(4):233-8 PMID: 16136847
  44. Dimebon in Alzheimer's disease: old drug for new indication.
    Lancet. 2008 Jul 19;372(9634):179-80 PMID: 18640436
  45. Influence of behavioral symptoms on rates of institutionalization for persons with Alzheimer's disease.
    Psychol Med. 2004 Aug;34(6):1129-35 PMID: 15554582
  46. Clinical trial of indomethacin in Alzheimer's disease.
    Neurology. 1993 Aug;43(8):1609-11 PMID: 8351023
  47. Memantine for agitation/aggression and psychosis in moderately severe to severe Alzheimer's disease: a pooled analysis of 3 studies.
    J Clin Psychiatry. 2008 Mar;69(3):341-8 PMID: 18294023
  48. Conjugal Alzheimer disease: risk in children when both parents have Alzheimer disease.
    Arch Neurol. 2008 Mar;65(3):373-8 PMID: 18332250
  49. Multitracer PET imaging of amyloid plaques and neurofibrillary tangles in Alzheimer's disease.
    Neuroimage. 2008 Nov 1;43(2):236-44 PMID: 18694837
  50. Longitudinal changes in cognition and behavior in asymptomatic carriers of the APOE e4 allele.
    Neurology. 2004 Jun 8;62(11):1990-5 PMID: 15184602
  51. A novel presenilin 1 mutation associated with Pick's disease but not beta-amyloid plaques.
    Ann Neurol. 2004 May;55(5):617-26 PMID: 15122701
  52. What does fluorodeoxyglucose PET imaging add to a clinical diagnosis of dementia?
    Neurology. 2007 Aug 28;69(9):871-7 PMID: 17724289
  53. Exercise, APOE, and working memory: MEG and behavioral evidence for benefit of exercise in epsilon4 carriers.
    Biol Psychol. 2008 May;78(2):179-87 PMID: 18395955
  54. PET amyloid ligand [11C]PIB uptake is increased in mild cognitive impairment.
    Neurology. 2007 May 8;68(19):1603-6 PMID: 17485647
  55. Beta-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease.
    Brain. 2007 Nov;130(Pt 11):2837-44 PMID: 17928318
  56. The clinical meaningfulness of ADAS-Cog changes in Alzheimer's disease patients treated with donepezil in an open-label trial.
    BMC Neurol. 2007 Aug 30;7:26 PMID: 17760991
  57. Apolipoprotein E type 4 allele and cerebral glucose metabolism in relatives at risk for familial Alzheimer disease.
    JAMA. 1995 Mar 22-29;273(12):942-7 PMID: 7884953
  58. Role of BDNF Val66Met functional polymorphism in Alzheimer's disease-related depression.
    Neurobiol Aging. 2009 Sep;30(9):1406-12 PMID: 18179845
  59. Genetic testing for Alzheimer's disease and its impact on insurance purchasing behavior.
    Health Aff (Millwood). 2005 Mar-Apr;24(2):483-90 PMID: 15757934
  60. Aspirin and non-steroidal anti-inflammatory drugs inhibit amyloid-beta aggregation.
    Neuroreport. 2001 Oct 29;12(15):3263-7 PMID: 11711868
  61. Exploring candidate gene associations with neuropsychological performance.
    Am J Med Genet B Neuropsychiatr Genet. 2007 Dec 5;144B(8):987-91 PMID: 17579348
  62. Amnestic mild cognitive impairment: structural MR imaging findings predictive of conversion to Alzheimer disease.
    AJNR Am J Neuroradiol. 2008 May;29(5):944-9 PMID: 18296551
  63. Differential age effects on cerebral blood flow and BOLD response to encoding: associations with cognition and stroke risk.
    Neurobiol Aging. 2009 Aug;30(8):1276-87 PMID: 18160181
  64. Correlations between apolipoprotein E epsilon4 gene dose and brain-imaging measurements of regional hypometabolism.
    Proc Natl Acad Sci U S A. 2005 Jun 7;102(23):8299-302 PMID: 15932949
  65. Dynamics of gray matter loss in Alzheimer's disease.
    J Neurosci. 2003 Feb 1;23(3):994-1005 PMID: 12574429
  66. PET of brain amyloid and tau in mild cognitive impairment.
    N Engl J Med. 2006 Dec 21;355(25):2652-63 PMID: 17182990
  67. Reduced functional brain activity response in cognitively intact apolipoprotein E epsilon4 carriers.
    Brain. 2006 May;129(Pt 5):1240-8 PMID: 16537568
  68. Familial risk for Alzheimer's disease alters fMRI activation patterns.
    Brain. 2006 May;129(Pt 5):1229-39 PMID: 16627465
  69. Major decrease in the volume of the entorhinal cortex in patients with Alzheimer's disease carrying the apolipoprotein E epsilon4 allele.
    J Neurol Neurosurg Psychiatry. 1998 Sep;65(3):322-7 PMID: 9728943
  70. Effect of dimebon on cognition, activities of daily living, behaviour, and global function in patients with mild-to-moderate Alzheimer's disease: a randomised, double-blind, placebo-controlled study.
    Lancet. 2008 Jul 19;372(9634):207-15 PMID: 18640457
  71. Effects of a 14-day healthy longevity lifestyle program on cognition and brain function.
    Am J Geriatr Psychiatry. 2006 Jun;14(6):538-45 PMID: 16731723
  72. Prediction of AD with MRI-based hippocampal volume in mild cognitive impairment.
    Neurology. 1999 Apr 22;52(7):1397-403 PMID: 10227624
  73. Alzheimer's disease: one disorder, too many genes?
    Hum Mol Genet. 2004 Apr 1;13 Spec No 1:R135-41 PMID: 14764623
  74. Clinical symptom responses to atypical antipsychotic medications in Alzheimer's disease: phase 1 outcomes from the CATIE-AD effectiveness trial.
    Am J Psychiatry. 2008 Jul;165(7):844-54 PMID: 18519523
  75. Medial temporal lobe function and structure in mild cognitive impairment.
    Ann Neurol. 2004 Jul;56(1):27-35 PMID: 15236399
  76. An active and socially integrated lifestyle in late life might protect against dementia.
    Lancet Neurol. 2004 Jun;3(6):343-53 PMID: 15157849
  77. fMRI evidence of compensatory mechanisms in older adults at genetic risk for Alzheimer disease.
    Neurology. 2005 Feb 8;64(3):501-8 PMID: 15699382
  78. Familial frontotemporal dementia associated with a novel presenilin-1 mutation.
    Dement Geriatr Cogn Disord. 2002;14(1):13-21 PMID: 12053127
  79. Cerebral blood flow and BOLD responses to a memory encoding task: a comparison between healthy young and elderly adults.
    Neuroimage. 2007 Aug 15;37(2):430-9 PMID: 17590353
  80. Longitudinal MRI findings from the vitamin E and donepezil treatment study for MCI.
    Neurobiol Aging. 2008 Sep;29(9):1285-95 PMID: 17452062
  81. Preclinical memory decline in cognitively normal apolipoprotein E-epsilon4 homozygotes.
    Neurology. 1999 Jul 13;53(1):201-7 PMID: 10408560
  82. NSAIDs and Alzheimer disease: epidemiological, animal model and clinical studies.
    Neurobiol Aging. 2007 May;28(5):639-47 PMID: 16697488
  83. Hippocampal volumes in cognitively normal persons at genetic risk for Alzheimer's disease.
    Ann Neurol. 1998 Aug;44(2):288-91 PMID: 9708558
  84. Specificity of brain activation patterns in people at genetic risk for Alzheimer disease.
    Am J Geriatr Psychiatry. 2002 Jan-Feb;10(1):44-51 PMID: 11790634
  85. Caring for a relative with dementia: family caregiver burden.
    J Adv Nurs. 2007 Jun;58(5):446-57 PMID: 17442030
  86. Reduced cortical thickness in hippocampal subregions among cognitively normal apolipoprotein E e4 carriers.
    Neuroimage. 2008 Jul 15;41(4):1177-83 PMID: 18486492
  87. Effect of rivastigmine in the treatment of behavioral disturbances associated with dementia: review of neuropsychiatric impairment in Alzheimer's disease.
    Curr Med Res Opin. 2005 Oct;21(10):1631-9 PMID: 16238903
  88. Does NSAID use modify cognitive trajectories in the elderly? The Cache County study.
    Neurology. 2007 Jul 17;69(3):275-82 PMID: 17636065
  89. fMRI studies of associative encoding in young and elderly controls and mild Alzheimer's disease.
    J Neurol Neurosurg Psychiatry. 2003 Jan;74(1):44-50 PMID: 12486265
  90. Behavioral and psychological symptoms and the progression of dementia of the Alzheimer type in nursing home residents.
    Med Sci Monit. 2008 Nov;14(11):CR559-67 PMID: 18971872
  91. Two novel presenilin 1 gene mutations connected with frontotemporal dementia-like clinical phenotype: genetic and bioinformatic assessment.
    Exp Neurol. 2006 Jul;200(1):82-8 PMID: 16546171
  92. Dementia patient suffering and caregiver depression.
    Alzheimer Dis Assoc Disord. 2008 Apr-Jun;22(2):170-6 PMID: 18525290
  93. Impact of APOE in mild cognitive impairment.
    Neurology. 2004 Nov 23;63(10):1898-901 PMID: 15557508
  94. Age-related total gray matter and white matter changes in normal adult brain. Part I: volumetric MR imaging analysis.
    AJNR Am J Neuroradiol. 2002 Sep;23(8):1327-33 PMID: 12223373
  95. Regional brain atrophy rate predicts future cognitive decline: 6-year longitudinal MR imaging study of normal aging.
    Radiology. 2003 Dec;229(3):691-6 PMID: 14657306
  96. Emotional responses to APO E genotype disclosure for Alzheimer disease.
    J Genet Couns. 2005 Apr;14(2):141-50 PMID: 15959645
  97. Predictive genetic testing for Alzheimer's disease: impact upon risk perception.
    Risk Anal. 2005 Apr;25(2):397-404 PMID: 15876213
  98. Brain imaging evidence of preclinical Alzheimer's disease in normal aging.
    Ann Neurol. 2006 Apr;59(4):673-81 PMID: 16470518
  99. Clinical and neuropathological features of the arctic APP gene mutation causing early-onset Alzheimer disease.
    Arch Neurol. 2008 Apr;65(4):499-505 PMID: 18413473
  100. A familial Alzheimer's disease locus on chromosome 1.
    Science. 1995 Aug 18;269(5226):970-3 PMID: 7638621
  101. Increased neurofibrillary tangles in patients with Alzheimer disease with comorbid depression.
    Am J Geriatr Psychiatry. 2008 Feb;16(2):168-74 PMID: 18239198
  102. Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial.
    Lancet. 2008 Jul 19;372(9634):216-23 PMID: 18640458
  103. Patterns of brain activation in people at risk for Alzheimer's disease.
    N Engl J Med. 2000 Aug 17;343(7):450-6 PMID: 10944562
  104. Cognitive function over time in the Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT): results of a randomized, controlled trial of naproxen and celecoxib.
    Arch Neurol. 2008 Jul;65(7):896-905 PMID: 18474729
  105. Cognitive-behavioral treatment for anxiety in patients with dementia: two case studies.
    J Psychiatr Pract. 2008 May;14(3):186-92 PMID: 18520790
  106. Activation of cerebral blood flow during a visuoperceptual task in patients with Alzheimer-type dementia.
    Neurobiol Aging. 1993 Jan-Feb;14(1):35-44 PMID: 8450930
  107. Cumulative effect of COMT and 5-HTTLPR polymorphisms and their interaction with disease severity and comorbidities on the risk of psychosis in Alzheimer disease.
    Am J Geriatr Psychiatry. 2006 Apr;14(4):343-51 PMID: 16582043
  108. Genetic variation in the alpha 7 nicotinic acetylcholine receptor is associated with delusional symptoms in Alzheimer's disease.
    Neuromolecular Med. 2008;10(4):377-84 PMID: 18696274
  109. Nongenetic factors as modifiers of the age of onset of familial Alzheimer's disease.
    Int Psychogeriatr. 2003 Dec;15(4):337-49 PMID: 15000414
  110. Prevalence of neuropsychiatric symptoms in mild cognitive impairment and normal cognitive aging: population-based study.
    Arch Gen Psychiatry. 2008 Oct;65(10):1193-8 PMID: 18838636
  111. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B.
    Ann Neurol. 2004 Mar;55(3):306-19 PMID: 14991808
  112. Behavioral and psychological symptoms in the preclinical stage of Alzheimer's disease.
    Med Sci Monit. 2008 Sep;14(9):CR473-9 PMID: 18758418
  113. Genetic aspects of Alzheimer disease.
    Genet Med. 2008 Apr;10(4):231-9 PMID: 18414205
  114. Neuropsychiatric impairments as predictors of mild cognitive impairment, dementia, and Alzheimer's disease.
    Am J Alzheimers Dis Other Demen. 2008 Aug-Sep;23(4):326-33 PMID: 18453641
Article Info
Journal
Annual review of clinical psychology
Abbr.
Annu Rev Clin Psychol
ISSN
1548-5951
DOI
10.1146/annurev.clinpsy.032408.153625
Email
sbook@ucla.edu
Published
2009-00-00
Pages
343-62
Language
English
Region
United States
NLM ID
101235325
PMCID
PMC3118550
Subset
IM
Grants
NIA NIH HHS · R01 AG013308 · United States
NIA NIH HHS · R01 AG013308-15 · United States
External Links
PubMed source DOI: 10.1146/annurev.clinpsy.032408.153625 PMC Full Text View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2